Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Partially aligned: the indications and IL-17A mechanism are supported by the provided label excerpts. However, many meal-timing/food-absorption claims and most administration timing/diet recommendations are not supported by the supplied prescribing information excerpts, leading to multiple unsupported statements and notable omissions for label-required administration guidance.
Category Scores
Accurate Statements
Cosentyx (secukinumab) is a biologic medication used to treat plaque psoriasis.
Supported by COSENTYX indication for moderate to severe plaque psoriasis (Sec. 1.1) and description as secukinumab IL-17A antagonist (provided context).
Cosentyx (secukinumab) is a biologic medication used to treat psoriatic arthritis.
Supported by COSENTYX indication for active psoriatic arthritis (Sec. 1.2).
Cosentyx (secukinumab) is a biologic medication used to treat ankylosing spondylitis.
Supported by COSENTYX indication for active ankylosing spondylitis (Sec. 1.3).
Cosentyx works by targeting and blocking the action of interleukin-17A (IL-17A).
Supported by Mechanism of Action: selectively binds IL-17A and inhibits its interaction with IL-17 receptor (Sec. 12.1).
Unsupported Statements
Cosentyx is administered by injection once a week.
The provided dosage excerpt specifies specific week-based loading schedules (e.g., Weeks 0,1,2,3,4) and then every 4 weeks thereafter for plaque psoriasis (Sec. 2.3), and other regimens for other indications. A blanket statement of 'once a week' is not supported by the supplied label excerpts.
Cosentyx can be taken without regard to food.
No food/meal-related administration statement is present in the provided label excerpts (Sections 1–8 and 12–14 excerpts).
Food can affect the absorption of biologics, including Cosentyx.
No absorption/food effect statement is provided in the supplied label excerpts.
A high-fat meal can slow the absorption of biologics, including Cosentyx.
No meal composition/absorption effect information is provided in the supplied label excerpts.
A low-fat meal can speed up the absorption of biologics.
No meal composition/absorption effect information is provided in the supplied label excerpts.
Taking Cosentyx with a meal may help minimize potential gastrointestinal side effects such as nausea and diarrhea.
The provided label excerpts do not describe meal-associated mitigation of nausea/diarrhea or GI side effects in relation to taking Cosentyx with food.
Taking Cosentyx on an empty stomach may help minimize potential gastrointestinal side effects.
The provided label excerpts do not describe empty-stomach effects on GI side effects.
Avoiding high-fat meals is recommended for timing Cosentyx to ensure optimal absorption.
No high-fat meal avoidance or 'optimal absorption' meal-timing guidance is provided in the supplied label excerpts.
Choosing a consistent meal schedule may help minimize potential side effects.
No consistent meal schedule guidance is provided in the supplied label excerpts.
The impact of meal timing on Cosentyx efficacy is being studied.
No statement about studies of meal timing/cosentyx efficacy is included in the supplied label excerpts.
There is no one-size-fits-all approach to meal timing with Cosentyx.
No meal timing guidance or 'no one-size-fits-all' statement is included in the supplied label excerpts.
There is no specific waiting period recommended after taking Cosentyx before eating.
No food/meal waiting period information is present in the supplied label excerpts; therefore the statement cannot be supported from the provided label.
It is generally recommended to wait at least 30 minutes to 1 hour before eating after taking Cosentyx.
No such waiting period is present in the supplied label excerpts.
Meal timing in relation to biologic therapy may impact efficacy and tolerability of treatment.
No meal timing impact on efficacy/tolerability is described in the supplied label excerpts.
Taking biologics, including Cosentyx, on an empty stomach may help minimize potential gastrointestinal side effects.
No label support for empty-stomach GI side effect mitigation is provided in the supplied label excerpts.
Contradictions
Low
AI Statement
There is no specific waiting period recommended after taking Cosentyx before eating.
Label Reference
Not directly contradictable as the provided label excerpts contain no meal/waiting-period guidance.
Important Omissions
COSENTYX pre-treatment evaluations: evaluate for active/latent TB and complete age-appropriate immunizations before initiating; and not recommended in active TB infection.
Importance:
Moderate
COSENTYX administration instructions/route details: subcutaneous use for pens/prefilled syringes/vials for IV only in adults; pediatric self-administration not recommended.
Importance:
Moderate
Label-directed monitoring/warnings: infection risk, TB monitoring during/after treatment, hypersensitivity reaction discontinuation guidance, and IBD monitoring caution.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported meal/food-timing claims could mislead about administration practices; additionally, omitted label safety requirements (e.g., TB evaluation/monitoring and immunizations) are material. However, no explicit contraindication or boxed-warning-contradicting safety claim is made in the provided response.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple unsupported food/meal-timing and GI-side-effect claims; one regimen-level dosing schedule statement is not consistent with label dosing details provided.
Suggested Improvement
Remove or qualify all meal/food/absorption timing claims unless supported by the specific FDA label sections provided. Replace 'once a week' with label-specific dosing regimens (loading vs maintenance; every-4-weeks where applicable) and include key label administration/safety instructions from Sections 2.1, 2.2, and Warnings/Precautions (TB evaluation/monitoring, immunizations, infection/hypersensitivity/IBD monitoring).